321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

Discover the exciting potential of amylin hormone treatments for obesity, promising fewer side effects than existing options. Dive into the impressive performance of Summit Therapeutics' cancer drug against Merck's Keytruda. Explore the mixed results from Recursion's AI-driven drug candidate and its implications for future development. Plus, get insights on the evolving landscape of obesity treatments and the challenges faced by various players in the pharmaceutical industry.